Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The firm is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Follow-Up Questions
ORHHF hissesinin fiyat performansı nasıl?
ORHHF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Orthocell Ltd için ana iş temaları veya sektörler nelerdir?
Orthocell Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
Orthocell Ltd 'in piyasa değerlemesi nedir?
Orthocell Ltd 'in mevcut piyasa değerlemesi $0 'dir
Orthocell Ltd al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 3 analist Orthocell Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 3 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
